Page 15 - Consensus Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Innovation 22 February, 2021 A survey explored non-pharmacological interventions as alternatives to pro re nata (as-required) psychotropic medication in mental health settings. This article explores its results, which have been developed into a clinical aid suggesting possible interventions. This article comes with a handout for a journal club discussion Abstract Pro re nata (as-required) psychotropic medicines are used frequently in mental health settings; however, concerns have been raised over the safety and lack of evidence of effectiveness of this practice. A mental health trust cond...

Louise Burke, Lindy Castell, Joanna Harper and Angela Cheruiyot Today – February 11 – marks the sixth annual International Day of Women and Girls in Science, established by the United Nations General Assembly “in order to achieve full and equal access to and participation in science for women and girls”. According to data for 2014 to 2016 produced by the United Nations Educational, Scientific and Cultural Organisation (UNESCO), only about 30% of all female students select fields related to science, technology, engineering and mathematics in higher education. “Long-standing biases an...

University of Warwick: COVID-19 vaccine impact forecast, 13 January 2021 Request an accessible format. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email contact@go-science.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use. Details NPIs) scenarios. This paper was presented at The paper is the assessment of the evidence at the time of writing. As new evidence or data emerges, SAGE updates its advice accordingly. NPIs. These documents are...

Imperial College London: Potential profile of the COVID-19 epidemic in the UK under different vaccination roll out strategies, 13 January 2021 Request an accessible format. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email contact@go-science.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use. Details NPIs) scenarios. It was considered at The paper is the assessment of the evidence at the time of writing. As new evidence or data emerges, ...

FDA approves GSK's BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US Approval builds on nearly 10 years of experience in lupus News provided by Share this article Share this article LONDON, Dec. 17, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BENLYSTA (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy. Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus (SLE), the most c...